Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy

SIMPLE SUMMARY: Tamoxifen is an important adjuvant endocrine therapy in estrogen receptor (ER)-positive breast cancer patients. It is mainly catalyzed by the enzyme CYP2D6 into the most active metabolite endoxifen. Genetic variation in the CYP2D6 gene influences endoxifen formation and thereby poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Tessa A. M., de With, Mirjam, del Re, Marzia, Danesi, Romano, Mathijssen, Ron H. J., van Schaik, Ron H. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917604/
https://www.ncbi.nlm.nih.gov/pubmed/33673305
http://dx.doi.org/10.3390/cancers13040771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917604/
https://www.ncbi.nlm.nih.gov/pubmed/33673305
http://dx.doi.org/10.3390/cancers13040771

Ejemplares similares